Board of Directors
Ole Vahlgren
Chairman of the board
25-years of experience as Senior Pharma Executive, and business development.
Chairman of the Board
Michael Ulveman
Board Member
Strategic communication specialist, who is advising companies, organizations and top-executives on communication and public affairs. He has worked for two Danish Prime Ministers and the NATO Secretary General on how to set the agenda in the public and navigate in a complex media environment. With +20 years as journalist, correspondent and editor, Michael has a profound insight in local and international media. Postings include Washington DC and Bruxelles. Today he is the Co-founder and partner in Denmarks leading communication agency, Ulveman & Børsting with a staff of 30 employees.
Board Member
Anders Vadsholt
Board Member
CFO and advisor of multiple companies including Orphazyme and Minervax
Board Member
Sebastian Wehle
Board Member
Sebastian Wehle, a (bio)pharmaceutical executive brings over 20 years of expertise in Manufacturing and Supply, Capital Program Management, and Asset Development. He has a successful track record of launching and supplying one of the first commercial stem cell products, as well as establishing and managing production facilities of various sizes and focus areas. As Chairman on executive-level Program Steering Committees in the past, he has overseen core network expansion strategies, general asset development initiatives, and launch activities.
Board Member
Anella Stelsig Rogaczewski
Board Member
Board Member
Management Team
Søren P.Sheikh
Chief Executive Officer
Plus 35 years of experience in Danish and US Universities and hospitals. Doctoral thesis in gut and neuropeptides and their 7TM receptors. Research activities have mainly focused on stem cell fate and differentiation (adipose derived stem cells and iPS cells and differentiation into cardiomyocytes and endothelial cells), and implementation of stem cell treatment in clinical medicine. In addition, research activities in molecular signaling mechanisms of 7 TM receptors, transcriptome and proteome profiling and use of AI in prostate cancer. Søren established the Danish Centre for Regenerative Medicine at Odense University Hospital (OUH). Søren was head of Dept. of Clinical Biochemistry & Pharmacology at OUH with 280 employees including 35 scientists for 15 years. Søren established and served as head of the Center for Vascular Regeneration at OUH/SDU, a center that implements stem cell treatments in clinical practice. Søren is and has been member of several editorial boards and other scientific advisory boards including the Research Council for Southern Denmark. Søren is a co-founder and CEO of Blue Cell Therapeutics, consisting of 14 employees.
Chief Executive Officer
Jakob Lerche Hansen
Cheif Scientific Officer
Chief Scientific Officer
Gitte L. Christensen
Director
Gitte has more than 20 years of experience within cell biology, assay development and research management. She has extensive experience with primary cells and substantial research experience from several areas, including cardiology, diabetes, cancer and osteoporosis. Gitte contributes with deep knowledge in research and development and experience with strategy and project development from positions at University of Copenhagen and Copenhagen University hospital.
Gitte is educated as a Cell biologist from University of Copenhagen and holds a PhD in medical Sciences from University of Copenhagen.
Director
Thomas Sandal
Chief Data Officer
Thomas is a biotech leader with 30+ years of experience within the Biotech and Biopharmaceutical industry. He has been responsible for early-stage discovery and CMC development of antibodies and antibody fragments within indications such as RA (Sub cutaneous delivered), ALI (pulmonary delivered), Psoriasis (topical delivered), oncology (CPI’s, ADC’s and autologous T cell therapy) and Microbiome bacterial consortia products. Thomas brings deep insight to biotech company building, R&D strategy, planning, implementation and prioritization from his executive and senior positions at PokeAcell, AGC Biologics, Microbiotica Ltd, Crescendo Biologics Ltd, GSK, Ltd. and Domantis. In these positions Thomas has progressed several compounds to clinical stages. Thomas graduated as a molecular biologist and holds a degree in engineering from the Technical University of Denmark and a Business Administration degree from Copenhagen University College of Engineering.
Chief Developer Officer
Team
Mette Søgaard Hansen
Senior Laboratory Technician
Cell biology & assay development
Marie-Louise Krogh
Senior Project Manager
Benjamin Claass
Senior Scientist
Research & CMC
Martha Seikh Chahid
Administrative Project Manager
Katrine Mark
Laboratory Manager
Elena Pedraz Cuesta
Senior Scientist
Research & Project Manager
MingShu Meng Eriksen
Senior Laboratory Technician
Cell biology & assay development
Maja Lind Nybo
Senior Scientist
In vivo biology & toxicology
Jone Marita Kvam
Research Scientist
In vivo biology
Visnja Radulovic
Senior Scientist
In vitro biology
Christoffer Valgreen
Student Assistant
Finance
Javier Ruiz Gonzalez
Student Assistant
Marketing
Advisory Board
Advisory Board Member
Klaus Brasso
Advisory Board Member
Klaus Brasso is a MD., PhD., senior consultant urologists and former professor at the Department of Urology, Rigshospitalet, University of Copenhagen Denmark. His primary focus area is prostate cancer, being involved in all aspects of managing men with prostate cancer, being involved in studies ranging from basic epidemiology to clinical trials in men with advanced disease. Klaus Brasso has been serving as a Danish representative in the Scandinavian Prostate Cancer Group.